Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine ER for ADHD in Children and Adolescents (Phase III, China)
CTR20171323Phase 3Active
- Sponsor
- Shandong Bainuo Pharmaceutical
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Shandong Bainuo Pharmaceutical. Started Nov 2017; status: active.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20171323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171323.